

In our October All-Member Webinar, TpAML co-founder/advocate Julie Guillot and Dr. Gwen Nichols, Chief Medical Officer, Leukemia & Lymphoma Society, highlighted the energy and work behind putting — and keeping — the patient at the center of drug development.
Participants had the opportunity to learn valuable insights on the makings of Target Pediatric AML (that a number of CAC2 members worked together on) and how research findings have spurred the launch of a groundbreaking global master clinical trial initiative in high-risk childhood leukemia, LLS PedAL.
Categories
- Blog Posts (65)
- Guest Blogs (18)
- Member Blogs (24)
- Survivorship Matters Blog (9)
- CAC2 News (21)
- Collaborative Achievements (13)
- Community News (170)
- News Digest (130)
- Research Explained (10)
- Webinars (61)
Tags
#CancelChildhoodCancer (1)
Advocacy (47)
Annual Summit (7)
Awareness (20)
AYA (2)
Best Practices (12)
Biorepositories (2)
CAC2 News (7)
CAC2 Project Incubator (1)
CAC2 Projects (11)
Call to Action (24)
Cancer Moonshot (1)
Clinical Trials (10)
COG (2)
Collaboration (11)
Comparative Oncology (1)
Data (15)
Delayed Diagnosis (2)
Digest (12)
Drug Development (12)
Drug Shortages (2)
Ethics (1)
Family Support (14)
FDA (1)
Funding Research (6)
Genomics (6)
Industry Perspective (5)
Member Access (12)
NCI (3)
Nutrition (1)
Patient-Reported Outcomes (1)
Prevention (5)
Psychosocial Support (4)
Rare and Ultra Rare Cancer (1)
Rare Cancers (1)
Regulations (3)
Research (38)
Research Advocacy (1)
Survivorship (26)
Venture Philanthropy (3)